Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
Executive Summary
After developing a seemingly ideal application and winning a history-making approval, Sandoz still faces a patent case, and then it would enter territory where it has stumbled before: pricing and marketing a complex product in a crowded market.